Preliminary data from a recently completed phase III clinical trial showed that eplontersen, a ligand conjugated PMO-ASO inhibiting transthyretin synthesis, had an acceptable safety profile and met co-primary and secondary endpoints among patients with polyneuropathy caused by hereditary transthyretin amyloidosis [167]. Here, TTR is linked to amyloidosis.